In 1995, IFN-α, a protein involved in immunomodulatory cell-cell signaling, including MHC I-based antigen recognition, chemokine production and secretion, and immune cell activation, among other anti-tumor properties [11], became the first and only FDA-approved adjuvant therapy for post-resection, high-risk MM. Here, IFNA1 is linked to Miyoshi myopathy.